Synergistic effect of prednisolone and omega-3 fatty acids revealed through in silico, in vitro, and in vivo approaches against APAP-induced mouse model of acute liver injury.

Regardless of being extensively used as an analgesic and antipyretic, APAP toxicity is a severe therapeutic problem. This research article tested the combination of a FDA approved corticosteroid drug, Prednisolone, with a pure compound, omega-3 fatty acids (ω-3), in the management of liver injury. Pred. and ω-3 were studied in male BALB/c mice after the acute liver injury had been induced by acetaminophen (APAP). The potency of this combination therapy in mitigating APAP-induced hepatotoxicity is investigated with a focus on elucidating the underlying molecular mechanisms. The therapeutic potential of the combination of this drug and compound is assessed by liver function tests, markers of oxidative stress, complete blood counts, and histopathological changes. The prednisolone and omega-3 combination induced greater suppression of liver inflammation. Finally, the omega-3 fatty acids appeared to assist in maintaining a balanced immune system throughout the treatment, and this would counter some of the immunosuppressing effects that are usually accompanied by the use of corticosteroids. The reduced levels of ALT and AST show that the combination of prednisolone and omega-3 fatty acids eliminated the evidence of liver damage and inflammation successfully.